期刊
ACTA PHARMACOLOGICA SINICA
卷 41, 期 7, 页码 911-927出版社
NATURE PUBL GROUP
DOI: 10.1038/s41401-020-0372-z
关键词
cancer; immunotherapy; nanobiomaterials; nanoparticles; liposomes; micelles; hydrogel; microneedles; dendritic cells (DCs)
资金
- National Science Fund for Distinguished Young Scholars [31525009]
- National Natural Science Foundation of China [31930067, 31800797, 31771096]
- National Key Research and Development Program of China [2017YFC1103502]
- China Postdoctoral Science Foundation [2018M631094, 2019M653410]
- 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYGD18002]
Immunotherapy, as a powerful strategy for cancer treatment, has achieved tremendous efficacy in clinical trials. Despite these advancements, there is much to do in terms of enhancing therapeutic benefits and decreasing the side effects of cancer immunotherapy. Advanced nanobiomaterials, including liposomes, polymers, and silica, play a vital role in the codelivery of drugs and immunomodulators. These nanobiomaterial-based delivery systems could effectively promote antitumor immune responses and simultaneously reduce toxic adverse effects. Furthermore, nanobiomaterials may also combine with each other or with traditional drugs via different mechanisms, thus giving rise to more accurate and efficient tumor treatment. Here, an overview of the latest advancement in these nanobiomaterials used for cancer immunotherapy is given, describing outstanding systems, including lipid-based nanoparticles, polymer-based scaffolds or micelles, inorganic nanosystems, and others.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据